The U.S. Congress earned praise from the Society of Nuclear Medicine and industry representatives for passing a bill that seeks to provide adequate reimbursement for radiopharmaceuticals, including Bexxar and Zevalin. "Thousands of patients will benefit and live longer if the government and private payers adequately reimburse highly effective radioimmunotherapies," SNM President Robert Atcher said.

Full Story:
Diagnostic Imaging

Related Summaries